Royalty Pharma plc (NASDAQ:RPRX) Receives $42.50 Consensus PT from Brokerages

Royalty Pharma plc (NASDAQ:RPRX - Get Free Report) has received a consensus recommendation of "Buy" from the five ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $42.50.

Separately, Citigroup reissued a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th.

Royalty Pharma Stock Performance

Royalty Pharma stock traded up $0.17 during midday trading on Tuesday, reaching $32.20. The stock had a trading volume of 3,442,452 shares, compared to its average volume of 3,259,813. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $18.56 billion, a PE ratio of 22.21, a P/E/G ratio of 2.31 and a beta of 0.50. Royalty Pharma has a 12 month low of $24.05 and a 12 month high of $34.20. The firm's 50-day moving average price is $32.52 and its 200 day moving average price is $29.45.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, research analysts predict that Royalty Pharma will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.73%. The ex-dividend date is Friday, May 16th. Royalty Pharma's dividend payout ratio (DPR) is 60.69%.

Institutional Investors Weigh In On Royalty Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of RPRX. Louisbourg Investments Inc. purchased a new stake in shares of Royalty Pharma during the 1st quarter valued at $28,000. MassMutual Private Wealth & Trust FSB raised its position in Royalty Pharma by 76.4% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 414 shares in the last quarter. Brooklyn Investment Group lifted its stake in Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 876 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of Royalty Pharma by 417.6% in the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 877 shares in the last quarter. Finally, Riverview Trust Co increased its position in shares of Royalty Pharma by 3,953.3% during the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 1,186 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.